HVIA
PVLA

Hudson Valley Investment Advisors’s Palvella Therapeutics PVLA Stock Holding History

Hudson Valley Investment Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,000
Closed -$2.4K – 193
2024
Q2 		$2.4K Buy
14,000
+13,825
+7,900% +$156K ﹤0.01% 181
2024
Q1 		$2.56K Hold
175
– – ﹤0.01% 178
2023
Q4 		$2.4K Hold
175
– – ﹤0.01% 181
2023
Q3 		$4.17K Hold
175
– – ﹤0.01% 184
2023
Q2 		$2.32K Hold
175
– – ﹤0.01% 199
2023
Q1 		$13.7K Hold
175
– – ﹤0.01% 209
2022
Q4 		$14.6K Buy
+175
New +$14.1K ﹤0.01% 216

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Valley Investment Advisors's PVLA Position: Q3 2024 in Review

Hudson Valley Investment Advisors sold out of Palvella Therapeutics (PVLA) in Q3 2024, closing a stake of 14,000 shares — an estimated $2.4K sold.

Hudson Valley Investment Advisors first reported a position in PVLA in Q4 2022 and held it in 7 quarters. The position peaked at $14.6K in Q4 2022. 25 funds tracked by Wall St. Rank hold PVLA as of Q3 2024.

  • Hudson Valley Investment Advisors reported no remaining Palvella Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Hudson Valley Investment Advisors sold 14,000 Palvella Therapeutics shares in Q3 2024, an estimated $2.4K.
  • Hudson Valley Investment Advisors first reported a position in Palvella Therapeutics in Q4 2022 and held it in 7 quarters.
  • Hudson Valley Investment Advisors's Palvella Therapeutics position peaked at $14.6K in Q4 2022.
  • 25 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2024.

Based on Hudson Valley Investment Advisors's 13F filing for Q3 2024, filed 25 Oct 2024.